Is Alnylam Pharmaceuticals (ALNY) The Best Growth Stock?

​On April 1, Barclays expert Eliana Merle maintained a Buy standing connected Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) with a terms people of $527. The standing comes aft the institution presented objective information connected its cardiovascular portfolio astatine the American College of Cardiology’s Annual Scientific Session. At the conference, the institution shared HELIOS-B survey results for Vutrisiran, its ATTR-CM therapy.

​Management noted that analyses covered quality-of-life gains, subgroup efficacy, and real-world adherence implicit 613.8 days, wherever 93.8% of patients stayed connected treatment. In a station hoc analysis, 8.0% of Vutrisiran patients progressed to precocious illness versus 10.7% connected placebo during the double-blind phase.

​That said, the institution posted beardown gains successful fiscal Q4 2025 results. It posted a gross of $1.10 billion, up 84.95% year-over-year. The EPS for the 4th came successful astatine $0.82.

​Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is simply a biopharmaceutical institution that develops and commercializes caller therapeutics based connected ribonucleic acerb interference.

While we admit the imaginable of ALNY arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 7 Hot Growth Stocks to Invest successful Right Now and 7 Ridiculously Cheap Stocks to Buy According to Wall Street Analysts. 

Disclosure: None. Follow Insider Monkey connected Google News.